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Introduction
Tissue engineering is a new development and in this
review we set out some of the principles that underlie it.
The potential applications of tissue engineering in medi-
cine are diverse, and as a basis for new treatments for
musculoskeletal diseases it is likely to have a major impact
in rheumatology and orthopaedics. The progress in
research in tissue engineering has been rapid, but it is
acknowledged that more basic research is necessary to
develop its full potential. This requires the formation and
close collaboration of interdisciplinary research teams.
One of the focus areas of tissue engineering in our
research programme is in cartilage replacement and we
summarise some of the strategies being pursued in this
area in the newly formed UK Centre for Tissue Engineer-
ing in the Universities of Manchester and Liverpool [1].
The principles of tissue engineering
Tissue engineering has emerged through a combination of
many developments in biology, material science, engineer-
ing, manufacturing and medicine. The strategies devel-
oped in tissue engineering involve a range of approaches,
the key element of which is the use of biologically based
mechanisms to achieve the repair and healing of damaged
and diseased tissues. This application distinguishes it
from the use of medical devices, and the delivery of an
assembled ‘tissue equivalent’ distinguishes it from a phar-
maceutical product. Tissue engineering addresses the
problem caused by many injuries and disease processes
that result in physically damaged tissues and organs in our
bodies which, if left unattended, repair imperfectly or not
at all. It is the intervention with an engineered tissue that
presents the prospect of achieving successful repair
where it would not otherwise occur.
Tissue engineering is part of new wave of developments in
biomedicine in which our scientific understanding of how
living cells function will enable us to gain control and
direct their activity to promote the repair of damaged and
diseased tissues. The potential for medical intervention
with a tissue engineering solution is seen nowhere better
than with the chronic, persistent leg ulcer, which, in a
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patient with diabetes, provides a constant source of dis-
comfort and incapacity. The patient does not lack the
inherent  capacity to heal a skin wound, but healing is
failing to occur naturally at the site of the ulcer. What are
lacking are the biological signals, chemical messengers
and physical cues that initiate the events of cell migration,
blood vessel formation and tissue assembly for normal
wound healing. If we can provide these biological signals
in a ‘tissue engineered’ package, we can kick-start a
repair process that can be completed by the patient’s
own tissues.
How can this be achieved? What forms the tissue engi-
neered package? The precise form will vary with the
medical application for which it is designed. There are,
however, two typical elements: one or more type(s) of
living cell with particular tissue functions; and a material
support that forms a structure for both culturing the cells
in the laboratory and the surgical delivery of the tissue
equivalent to the patient. This support might be in the form
of a lamella or tubular structure, or in a more complex
three-dimensional structure, depending on the clinical
application. The ‘package’ therefore contains several
important, and quite different, material components and its
assembly involves a manufacturing process that extends
from the culture of living cells to the fabrication techniques
for 3-dimensional structures, involving engineering and
bioreactor design. It also has to be carried out in a regula-
tory framework that will ensure the monitoring and docu-
menting of all stages of the process. Tissue engineering
thus requires the coordination of a range of different disci-
plines and its development depends on bringing together
broadly based research teams to form interdisciplinary col-
laborations, such as within our research programme at UK
Centre for Tissue Engineering, Universities of Manchester
and Liverpool [1]. Input is required from cell biologists,
molecular biologists, biomaterial scientists, bioengineers
and healthcare physicians.
Post genomic research and stem cells
A key to new developments in tissue engineering lies in
the current progress in research on living cells. Sequenc-
ing the human genome is close to completion and it is one
of the inevitable benefits of the post genomic age that a
more complete knowledge of the biological signals and
cues that trigger natural repair processes will be discov-
ered. It is this knowledge that will be exploited in tissue
engineering applications. So, the strategies behind current
developments in tissue engineering depend heavily on
living cells and tissues, and on our abilities to control their
function. The theme that is particularly emphasised in our
programmes is that, in many clinical applications, the
planned long-term solution will engage the patient’s own
cells and tissues in the process to complete a biological
repair. This is where it differs from the established use of
medical devices that have been very successful in some
applications, such as joint replacements, but in which the
damaged tissues are replaced with inert nonbiological
materials. The applications of tissue engineering will be
more diverse than has been possible with the nonbiologi-
cal devices. These will range from small blood vessel
replacement, repair of bone, tendon, ligament and carti-
lage, healing of skin wounds, nerve regeneration and the
repair of problems causing incontinence, to a range of
applications in reconstructive surgery. It may also extend
to cellular based therapies for degenerative problems in
muscle, heart and brain.
To help fuel these aspirations, there are remarkable new
developments in stem cell research, which show that we
all contain sources of cells that retain the capacity to form
the different tissues in our bodies [2]. In addition to embry-
onic stem cells, which in early embryonic development
have all the potential to divide and form all the tissues of
the body, it is now recognized that, even as adults, we all
contain some cells that retain the ability to form different
tissues. It has long been known that these cells can be
found in bone marrow (stromal stem cells) but, more
recently, evidence has suggested that they can be found
in other sites in the body and can even, for example, be
harvested from the fat removed at liposuction! There is
great interest in these sources of cells for tissue engineer-
ing applications, although much research is needed
before their full potential (and limitations) will be known.
Research on the biomaterials associated with tissue engi-
neering was initiated ahead of the developments in cell
biology. There is currently much research and innovation
in the development of new biomaterials. These extend
from well-tried polylactates and polyglycolates to novel
ceramics, caprolactones and hydrogels. Techniques are
being developed for their formation into scaffolds, felts
and weaves. Matrix printing devices are being explored for
the fabrication of three-dimensional structures with
microarchitecture that might mimic complex living organs,
such as liver or kidney tissues. Different applications
require different material properties to cope both with the
required tensile and compressive forces and with elastic
deformation and compliance. There is also much innova-
tion occurring in polymer chemistry, but each new polymer
or biomaterial requires extensive evaluation to assess how
it interacts with living tissue, how long it survives in the
body, what wear-products it produces and how it
degrades. The ability to generate new chemistry currently
far outpaces the speed at which their biological advan-
tages and disadvantages can be thoroughly assessed.
There is also considerable interest in the use of natural
biopolymers for tissue engineering applications, such as
the long chain polysaccharide hyaluronan and its chemi-
cally derivatised forms, and various preparations of natural
and recombinant proteins, including collagens and evenS65
silk. Many of these materials provide the opportunity for
chemically linking biological signaling molecules such as
peptides or small proteins, to provide sources of the signal-
ing molecules that will trigger cell responses to help the
healing process. For example, these ‘smart’ materials could
be used to provide signals to encourage blood vessel
development. When an engineered tissue is placed in the
body, it requires the development of a blood supply from
the patient for it to become integrated with surrounding
tissues; this is essential for the completion of the healing
process. The principle exceptions are cartilage, interverte-
bral disc and cornea, which are largely avascular tissues.
Strategies for articular cartilage repair
Articular cartilage provides its own particular challenges
for tissue engineering. Its structure appears simple and it
only contains one cell type; however it is has a complex
highly organised extracellular matrix (ECM). Articular carti-
lage is frequently damaged as a result of trauma and
degenerative joint diseases that may be driven by changes
in biomechanics, cytokines, growth factors and cellular
responses [3–6]. Cartilage has no blood vessels, it is not
innervated and normal mechanisms of tissue repair, involv-
ing the recruitment of cells to the site of damage, do not
occur. The challenge for cartilage tissue engineering is to
produce cartilage tissue with suitable structure and prop-
erties  ex vivo, which can be implanted into joints to
provide a natural repair that with time will become inte-
grated with the patient’s tissues.
The physical properties of articular cartilage depend on
the structure and organization of the macromolecules in
the ECM. They can largely be understood in terms of the
contribution made by fibrillar and nonfibrillar components
[5]. The structure of collagen gives it impressive tensile
properties, which are utilized in a special way in the pre-
dominant type II collagen, found in cartilage, to produce a
tissue that is not only strong in tension but also resistant
to compression. This is achieved by filling the interfibrillar
matrix with a very high content of proteoglycan, primarily
aggrecan [7,8], which draws water into the tissue as it
creates a large osmotic swelling pressure. The osmotic
pressure caused by the negatively charged groups on
aggrecan create a large difference in the concentration of
ions inside the cartilage compared with outside. Water is
drawn into the tissue as a result of this osmotic imbalance
and, because aggrecan is assembled into large supramol-
ecular aggregates [9], it is too large and immobile to redis-
tribute itself. The water thus swells and expands the
aggrecan-rich matrix. This places the collagen network
under tension and an equilibrium is achieved when tension
in the collagen network balances the swelling pressure.
This confers the tissue with compressive resilience and,
as aggrecan offers great resistance to any fluid flow, the
tissue behaves as a stiff elastic polymer to sudden impact
loading, but shows some slow inelastic deformation with
sustained loads. The articular cartilage thus forms a tough
but compliant load-bearing surface and these characteris-
tics depend on the integrity of the collagen network and
on the retention within it of a high concentration of aggre-
can. Part of the challenge of tissue engineering cartilage is
thus to provide the essential cells and signals that will
establish a cartilage ECM and recapitulate this molecular
organisation that forms the basis for the essential mechan-
ical properties of the tissue.
Our tissue engineering approaches to cartilage repair are
focussing on developing efficient methods to form carti-
lage with chondrocytes in culture. This approach depends
on the availability of suitably differentiated chondrocytes to
produce and maintain the specialised ECM of the tissue.
These cells may be obtained through culturing primary
autologous/heterologous chondrocytes [10], mesenchy-
mal stem cells [11] and embryonic stem cells [12]. An
important factor is the production of chondrocytes in suffi-
cient numbers to form tissue constructs of an appropriate
size. In the case of autologous chondrocytes, the expan-
sion of the cell population can be carried out in monolayer
culture conditions, although during this process chondro-
cytes become fibroblastic and lose their characteristic
pattern of matrix protein expression [13]. Our initial
studies are focussing on human articular chondrocytes,
their expansion in monolayer culture under differing condi-
tions and their subsequent potential to re-express a full
matrix-producing phenotype.
Gene expression in chondrocytes passaged in
monolayer culture
Human articular cartilage was obtained with informed
consent from knee replacement operations. The cartilage
from regions of the joints with intact tissue were dissected
from the underlying bone, chopped finely and digested,
first in trypsin for one hour, and subsequently overnight, in
0.08% bacterial collagenase in medium containing 10%
foetal bovine serum. Both digestions were at 37°C with
constant agitation. Washed, filtered cells were cultured as
monolayers in DMEM, containing penicillin/streptomycin
and 10% foetal bovine serum. The cells were split at a 1:2
ratio at confluence.
RNA was isolated from chondrocytes at various passages,
to build up an initial profile of the changes in gene expres-
sion during cell expansion. The level of mRNA expression
of a number of ECM markers (including chondrocyte-spe-
cific ECM genes [collagen II and aggrecan] and a fibrob-
last ECM gene [collagen I]) was assessed using RT-PCR.
In addition, the expression of transcription factors impor-
tant to chondrogenesis (SOX9, L-SOX5 and SOX6
[13,14]), of developmentally regulated cartilage genes
associated with the further differentiation and hypertrophy
of chondrocytes (matrilin-1, indian hedgehog and collagen
X) and of other genes (such as the recently cloned xylosyl-
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transferase isoforms [15]) was examined. Probes for these
different genes have been designed and tested in the
development of specific and sensitive methods to follow
changes in gene expression. The changes in expression of
these genes in chondrocytes with increasing passage in
culture are shown in Fig. 1.
Expression of chondrocyte-specific genes, such as colla-
gen II and aggrecan, decreased with time in culture, whilst
collagen I expression increased, as previously reported
[16]. Developmentally regulated gene transcripts charac-
teristic of chondrocyte hypertrophy were not expected to
be found in significant quantities in mature articular carti-
lage. Only very low expression of collagen X and indian
hedgehog was detected at any stage of monolayer
culture. Matrilin-1, however, was detected and its expres-
sion tended to increase with culture time. Matrilin-1 is
expressed in other nonarticular cartilages and the signifi-
cance of the expression in articular chondrocytes is cur-
rently unknown. Xylosyltransferase expression was
examined as a possible indicator of the glycosaminoglycan
synthesis of the cells. Two human isoforms have been
cloned, but the expression level of both was low and
remained the same throughout the culture period.
These initial studies have been extended by using real
time, quantitative RT-PCR for the analysis of gene expres-
sion levels. This has major advantages over normal RT-
PCR as it provides an accurate quantitative assay of gene
expression. Polymerase chain reactions have been con-
ducted using an Applied Biosystems 7700 and the ampli-
fied product was detected using the fluorescent DNA
binding dye SYBR Green. This technique has enabled us
to gain accurate data representing changing expression
levels between cultured chondrocytes and those freshly
isolated from the tissue. Results (Fig. 2) show that the
upregulation of collagen I is rapid following the isolation of
chondrocytes and their transfer into monolayer culture,
and it precedes the downregulation of collagen II. Down-
regulation of the transcription factors SOX9 and L-SOX5
also precedes changes in collagen II expression. It is also
clear that these changes in gene expression are largely
complete by passage 5, with little difference between this
stage and further culture up to passage 12.
Rates of chondrocyte proliferation
The effects of selected growth factors have also been
investigated on the chondrocytes cultured in 10% serum.
Published studies, screening an extensive number of
growth factors and media supplements [16], have
reported that human chondrocytes proliferate most rapidly
in medium supplemented with 10% foetal calf serum,
platelet-derived growth factor-BB, fibroblast growth
factor-2 (FGF-2) and transforming growth factor β-1.
When medium containing these supplements was added
to human articular cartilage cells at passage 4, they began
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Figure 1
The changes in expression of genes in human articular cartilage
chondrocytes with increasing passage in culture, detected using RT-
PCR. Passage 0 refers to cells that are freshly isolated from the tissue
and have not been cultured. GAPDH, glyceraldehyde phosphate
dehydrogenase; IHH, indian hedgehog; XT, xylosyltransferase.
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Figure 2
Real time RT-PCR analysis of RNA from human articular cartilage
chondrocytes at different passage in culture. The values shown are
expression levels of the indicated genes relative to the expression level
found in passage (P) 0 cells that are freshly isolated from the tissue.
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to divide far more rapidly than parallel cultures in just 10%
serum. The same was evident in these cells cultured in the
supplemented medium from the beginning of the first
passage. Cells seeded in 24-well plates at 2000 cells/well
were counted in medium containing 10% serum, 10%
serum + 5 ng/ml FGF-2 or 10% serum, 5 ng/ml fibroblast
growth factor-2 (FGF-2), 10 ng/ml platelet derived growth
factor-BB and 1ng/ml transforming growth factor β-1
(‘PTF media’) after 6 and 10 days in culture (Fig. 3). At
6 days, the number of cells in PTF-treated wells was twice
that of those in either the control or FGF-2-treated wells,
whilst by ten days the difference was ten-fold. This growth
factor combination was extremely effective in achieving a
rapid expansion of human chondrocytes in culture.
Re-expression of chondrogenic phenotype
A further aim of this project is to quantify the extent to
which chondrocytes can re-express a chondrocyte pheno-
type once placed in a three-dimensional culture environ-
ment. The SOX transcription factors, particularly SOX9,
appear to be sensitive indicators of the differentiation state
of the cell and the expression levels of these genes, as well
as those of collagen I, II and aggrecan, will be compared
with those of freshly isolated cells. It will be important to
determine if the rapid expansion of cell numbers in mono-
layer culture is detrimental or beneficial to their chondro-
genic potential. We have developed sensitive methods of
assessing the matrix assembly around chondrocytes,
based on determining by confocal fluorescence recovery
after photobleaching (confocal-FRAP) the translational dif-
fusion of fluorescent tracer molecules of defined size
[17–21]. This will be used to optimize conditions for matrix
assembly and develop neocartilage constructs that can
form the basis for a tissue engineered product.
Future prospects
Research in tissue engineering is expanding fast world-
wide [22], and new UK [23], European [24], Japanese
[25] and International [26] societies have begun to
provide a forum for worldwide developments. Current
advances in cell biology arising in post genomic research
will have a major impact on tissue engineering pro-
grammes. This will be complemented by the development
of novel biomaterials and fabrication methods that will aid
the design and effective delivery of tissue engineering
treatments to the patient. It is likely that tissue engineering
products will become commonplace within 20 years, but it
is important to perform a full cost/benefit analysis for such
treatments if they are to be funded and fully exploited
within the tough constraints of healthcare budgets, such
as those in the UK.
Concluding remarks
The application of tissue engineering provides new possi-
bilities for therapeutic intervention and will extend what
can be done for individuals with many chronic conditions
such as arthritis. A greater focus on strong basic research
is now helping to convert some of the past hype in tissue
engineering into practical applications.
Glossary of terms
Confocal-FRAP = a technique using the analysis of fluo-
rescent recovery after photobleaching with a confocal
microscope to measure self-diffusion and tracer diffusion
in polymer networks, such as those found in tissue extra-
cellular matrix; ECM = extracellular matrix; PTF medium =
medium containing 10% serum, 5ng/ml FGF-2, 10ng/ml
platelet-derived growth factor-BB and 1ng/ml transform-
ing growth factor β-1; SOX genes = (from 'Sry-type high-
mobility-group-box') a family of genes that encode for
transcription factors important during tissue development;
these genes all contain a Sry-type high-mobility-group box,
which is a protein motif involved in DNA binding; SOX9,
L-SOX5 and SOX6 are expressed in chondrocytes.
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